Login to Your Account

Revance ups IPO, gets $96M for topical form of Botox in phase III

By Randy Osborne
Staff Writer

Thursday, February 6, 2014
Topical Botox developer Revance Therapeutics Inc. priced its initial public offering (IPO) at the top of the projected range, sold more shares than expected and came out of the gate strong, with the stock (NASDAQ:RVNC) closing Thursday at $26.85, up $10.85, or 67.8 percent.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription